[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-433774-105":59,"doc-detail-433774-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","winners-of-the-2022-honor-awards-for-excellence-at-the-annual-meeting-of-the-chinese-medical-association-taipei-part-i","Winners of the 2022 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei - Part I","","Editorial “Part I” presents three winners of the 2022 Excellent Research Paper Awards announced at the Chinese Medical Association-Taipei Annual Meeting in July 2023. It summarizes scientific and practical findings from selected 2022 JCMA research. A featured study evaluates repeated loco-regional therapies for hepatocellular carcinoma after living donor liver transplantation, reporting worse survival with higher LRT frequency. The editorial also discusses established staging concepts, Milan criteria, survival/DFS effects, recurrence implications, and the alignment between life-saving and quality-of-life goals in cancer care.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/winners-of-the-2022-honor-awards-for-excellence-at-the-annual-meeting-of-the-chinese-medical-association-taipei-part-i/433774/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/winners-of-the-2022-honor-awards-for-excellence-at-the-annual-meeting-of-the-chinese-medical-association-taipei-part-i/433774.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What awards are highlighted in this editorial, and where were they announced?","Question",{"text":113,"@type":114},"The editorial covers the 2022 Excellent Research Paper Awards of the Journal of the Chinese Medical Association. They were announced at the Chinese Medical Association-Taipei Annual Meeting held in Taiwan in July 2023.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What study is specifically discussed regarding hepatocellular carcinoma and living donor liver transplantation?",{"text":118,"@type":114},"The editorial summarizes research by Dr Tsou and colleagues on repeated loco-regional therapies for hepatocellular carcinoma after living donor liver transplantation in cirrhotic patients, examining recurrence and survival outcomes.",{"name":120,"@type":111,"acceptedAnswer":121},"How does loco-regional therapy frequency relate to overall survival and disease-free survival?",{"text":122,"@type":114},"Results reported in the editorial show significantly better overall survival and disease-free survival for patients without previous LRT, while LRT frequency above a stated threshold (over 4 times) is linked to markedly shortened survival endpoints.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},433774,1790795812,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":39,"preview_page_count":4},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","J Chin MedAssoc  \nEditorial  \nWinners of the 2022 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part I  \nSzu-Ting Yanga,b,c, Chia-Hao Liua,b,c, Peng-Hui Wanga,b,c,*  \naDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cFemale Cancer Foundation, Taipei, Taiwan, ROC  \nThe 2022 Excellent Research Paper Awards of the Journal of the Chinese Medical Association (JCMA) were announced at  \nthe Chinese Medical Association-Taipei Annual Meeting (CMATaipei) on July 8 and July 9, 2023, held at Taipei, Taiwan. All outstanding research works have been selected from the 2022 issues of the JCMA, which is a general and popular medical journal with the achievement of 2022 new impact factor (IF) as 3.0. The present editorial is a “Part I,” including three excellent works.1–3 We are honored to present three winners and summary their impressive, scientific and useful findings, which bring a great impact on global health promotion and offer a better care reference for the profession in the management of various kinds of patients with similar clinical situation in the future.  \nThe publication entitled “Repeated loco-regional therapies for hepatocellular carcinoma is associated with inferior outcome after living donor liver transplantation in cirrhotic patients” was conducted by Dr Tsou and his colleagues.1 Among 124 patients with hepatocellular carcinoma (HCC) treated by living donor liver transplantation (LDLT) procedure, 18 patients had recurrence and 32 patients died during a median follow-up period of 41 months.1 Traditionally, the therapy of HCC patients is based the Barcelona Clinic Liver Cancer (BCLC) stage system.4–6 Noncirrhotic HCC patients with BCLC stage 0-A could be treated with resection surgery or local ablation.4,5 HCC patients with multiple tumors or BCLC stage Band preserved liver function could be treated with transarterial chemoembolization (TACE) .4–6 Systemic therapy is appropriate in patients with BCLC stage C.6 Many HCC patients were associated with cirrhosis (end-stage liver disease) . Cirrhotic HCC patients who meet Milan criteria are candidates for liver transplantation. The loco-regional therapies (LRTs) could be served as a bridging therapy for patients with HCC on the waitlist for  \n* Address correspondence. Dr Peng-Hui Wang, Department of Obstetricsand Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei, 112, Taiwan, [ROC. E-mail addresses:phwang@vghtpe.gov.tw](ROC. E-mail addresses:phwang@vghtpe.gov.tw); [pongpongwang@gmail.com](pongpongwang@gmail.com) (P.-H. Wang).  \nConflicts of interest: Dr Peng-Hui Wang, an editorial board member at the Journal of the Chinese Medical Association, had no role in the peer-review process of or decision to publish this article. The other authors declare no conflicts of interest related to the subject matter or materials discussed in this article.  \nJournal of Chinese Medical Association. (2023) 86: 777-779.  \nReceived July 10, 2023; accepted July 11, 2023.  \ndoi: 10. 1097/JCMA.0000000000000963.  \nCopyright © 2023, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/)[by-nc-nd/4.0/](by-nc-nd/4.0/))  \n[www.ejcma.org](www.ejcma.org)  \nliver transplant, or a strategy of downstaging to meet Milan criteria. However, it is still uncertain whether LRT may affect the outcome of LDLT or not. Tsou et al tried to respond to this question.1 The results showed a significantly better overall survival (OS) and disease-free survival (DFS) in the group of LDLT without previous LRT (5-year OS 87.5% vs 61.7%, p = 0.012; 5-year DFS 100.0% vs 70.7%, p = 0.001) .1 Moreover, LRT > 4 times was a critical redline, because OS and DFS were","cbCaicbfa2oEw5jW","https://ap.wps.com/l/cbCaicbfa2oEw5jW","pdf",294437,"English","# Editorial\n## 2022 Excellent Research Paper Awards and announcement\n## Featured study: LRT and outcomes after LDLT for HCC\n## Clinical staging framework and transplant criteria\n## LRT frequency threshold and survival analysis\n## Recurrence implications and quality-of-life perspective","[{\"question\":\"What awards are highlighted in this editorial, and where were they announced?\",\"answer\":\"The editorial covers the 2022 Excellent Research Paper Awards of the Journal of the Chinese Medical Association. They were announced at the Chinese Medical Association-Taipei Annual Meeting held in Taiwan in July 2023.\"},{\"question\":\"What study is specifically discussed regarding hepatocellular carcinoma and living donor liver transplantation?\",\"answer\":\"The editorial summarizes research by Dr Tsou and colleagues on repeated loco-regional therapies for hepatocellular carcinoma after living donor liver transplantation in cirrhotic patients, examining recurrence and survival outcomes.\"},{\"question\":\"How does loco-regional therapy frequency relate to overall survival and disease-free survival?\",\"answer\":\"Results reported in the editorial show significantly better overall survival and disease-free survival for patients without previous LRT, while LRT frequency above a stated threshold (over 4 times) is linked to markedly shortened survival endpoints.\"}]","Winners of the 2022 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei - Part I | PDF",1790665462]